Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
P/E Ratio
--
P/B Ratio
13.03
Industry P/E
--
Debt to Equity
0
ROE
-1.51 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.04
CFO
$-64.91 Mln
EBITDA
$-72.69 Mln
Net Profit
$-74.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Edesa Biotech (EDSA)
| 34.53 | -5.44 | 33.73 | -47.99 | -51.50 | -32.53 | -50.26 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Edesa Biotech (EDSA)
| -69.78 | -61.63 | 32.47 | 3.66 | -24.91 | -83.79 | -60.09 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.42 | 724.11 | -- | -14.75 | |
| 7.75 | 1,064.38 | 193.75 | 1.52 | |
| 3.54 | 150.42 | -- | -53.27 | |
| 35.11 | 2,528.21 | -- | -27.85 |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are... EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. Address: 100 Spy Court, Markham, ON, Canada, L3R 5H6 Read more
CEO, Company Secretary & Director
Dr. Pardeep Nijhawan FRCPC, M.D.
CEO, Company Secretary & Director
Dr. Pardeep Nijhawan FRCPC, M.D.
Headquarters
Markham, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Edesa Biotech Inc (EDSA) stood at $ 6 Mln as on 31-Dec-24
The share price of Edesa Biotech Inc (EDSA) is $2.26 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Edesa Biotech Inc (EDSA) has given a return of -51.5% in the last 3 years.
Edesa Biotech Inc (EDSA) has a market capitalisation of $ 16 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Edesa Biotech Inc (EDSA) is 13.03 times as on 16-Apr-2025, a 364% premium to its peers’ median range of 2.81 times.
Since, TTM earnings of Edesa Biotech Inc (EDSA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Edesa Biotech Inc (EDSA) and enter the required number of quantities and click on buy to purchase the shares of Edesa Biotech Inc (EDSA).
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. Address: 100 Spy Court, Markham, ON, Canada, L3R 5H6
The CEO & director of Dr. Pardeep Nijhawan FRCPC, M.D.. is Edesa Biotech Inc (EDSA), and CFO & Sr. VP is Dr. Pardeep Nijhawan FRCPC, M.D..
There is no promoter pledging in Edesa Biotech Inc (EDSA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
23
|
| Edesa Biotech Inc. (EDSA) | Ratios |
|---|---|
|
Return on equity(%)
|
-238.11
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Edesa Biotech Inc (EDSA) was $0 Mln.
$-0.08
(
